Argatroban Market size is forecast to reach 1.37 Billion by 2025, growing a CAGR of 3.25 during the forecast period 2020-2025. Argatroban is used with aspirin to treat and prevent harmful blood clots and it blocks certain natural substances that the body uses to form blood clots. Heparin is a more commonly used thrombin inhibitor, but it results in deficiency of blood platelet count in some cases and argatroban caters to this need by acting as a thrombin inhibitor without leading to any heparin like complications are the major factors driving the growth of the market. The characteristics of hepatic mechanism is increasing the use of argatroban in the patients with renal dysfunction and this tends to increase the overall market demand of argatroban during the forecast period 2020-2025.
- North America dominates the Argatroban Market owing to its high consumption and increasing number of patients with heptatic impairment. The Argatroban Market scope for different regions will be provided in the final report.
- Increase of thrombosis in individuals and heparin induced thrombocytopenia is likely to aid in the market growth of argatroban.
- Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Argatroban Market report.
- Low molecular weight and argatroban does not induce formation of antibodies that can alter its clearance and the high cost of argatroban is set to create hurdles for the Argatroban Market.
Product- Segment Analysis
The Argatroban powder segment held the largest share in the Argatroban Market in 2019 and is estimated to grow at a CAGR of 4.37% during the forecast period 2020-2025. The growth in this segment can be attributed to the fact that argatroban powder is a white, odorless crystalline powder that is freely soluble in glacial acetic acid, slightly soluble in ethanol, and insoluble in acetone, ethyl acetate and ether which is used as an anticoagulant in individuals with thrombosis and heparin-induced thrombocytopenia and its elimination half-life is about 39 and 51 minutes. It is also used to treat conditions such as heparin-induced thrombocytopenia (HIT). Heparin is a more commonly used thrombin inhibitor, but it results in deficiency of blood platelet count in some cases. It is estimated that argatroban injection which is a sterile clear, colorless to pale yellow, slightly viscous solution and is available in 250-mg (in 2.5-mL) single-use amber vials, with gray flip-top caps is estimated to be the fastest growing segment and is poised to register a highest CAGR during the forecast period 2020-2025.
Application – Segment Analysis
Heparin induced thrombocytopenia held major share in the Argatroban Market in 2019. This is owing to the complications of heparin therapy. There are two types of Heparin induced thrombocytopenia. Type 1 Heparin induced thrombocytopenia presents within the first 2 days after exposure to heparin, and the platelet count normalizes with continued heparin therapy. Type 1 Heparin induced thrombocytopenia is a nonimmune disorder that results from the direct effect of heparin on platelet activation. Type 2 Heparin induced thrombocytopenia is an immune-mediated disorder that typically occurs 4-10 days after exposure to heparin and has life- and limb-threatening thrombotic complications. Heparin-induced thrombocytopenia segment is set to be the fasting growing segment and is estimated to register a highest CAGR during the forecast period 2020-2025.
Geography – Segment Analysis
North America hold major share of 33.9% of total Argatroban Market followed by Asia Pacific. North America dominates the argatroban market owing to its high consumption among patients. Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Owing to its hepatic metabolism, it is used in patients with renal dysfunction and this is increasing the demand of argatroban market in the North America region.
However, Asia-Pacific is estimated to grow at a higher CAGR during the forecast period 2020-2025 owing to the need of argatroban which act as a thrombin inhibitor without leading to any heparin-like complications and also owing to the increase in the number of heparin-related complications among patients and rise in incidence of percutaneous coronary intervention procedures & cerebral arterial thrombosis
Drivers – Argatroban Market
- Increase of thrombosis in individuals and heparin induced thrombocytopenia
Increase of thrombosis in individuals and heparin induced thrombocytopenia is boosting the growth of the argatroban market. Cardiology Patient Page focuses on heparin-induced thrombocytopenia (HIT), a complication of heparin therapy. Heparin induced thrombocytopenia can often be diagnosed by measuring the platelet count and PF4 antibody level in the blood. Direct thrombin inhibitors are a class of anticoagulant medications that do not cause HIT. These drugs are administered by continuous intravenous infusion. The use of argatroban in patients with HIT and HITTS is associated with improvement in clinical outcomes compared with historical controls. Argatroban offers several practical advantages over other available agents with respect to dosing, monitoring, reversibility of effect with discontinuation of the drug, and cost.
- Argatroban as an anticoagulant in individuals
Argatroban is used as an anticoagulant in individuals is also driving the growth of the argatroban market. Individuals require long-term anticoagulation. If warfarin is chosen as the long-term anticoagulant, this poses particular challenges owing to the falsely elevated prothrombin time and INR caused by argatroban. Argatroban is metabolized in the liver and has a half-life of about 50 minutes. It is monitored by PTT. Owing to hepatic metabolism, it is set to be used in patients with renal dysfunction.
Challenges – Argatroban Market
- Low molecular weight and argatroban does not induce formation of antibodies
Some of the factors that is set to impede the growth of the argatroban market are Low molecular weight and argatroban does not induce formation of antibodies that can alter its clearance and also owing to increase in allergies associated with argatroban is set to to hinder the market growth.
Argatroban Industry Outlook
Product launches, mergers and acquisitions, joint ventures and R&D activities are key strategies adopted by players in the argatroban market. In 2019, Argatroban Market share is consolidated by the top ten players present in the market. Argatroban top 10 companies are Pfizer, GlaxoSmithKline, SANDOZ, Eagle Pharmaceuticals, Fresenius Kabi, Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, and WEST-WARD, among others.
- In December 2018, GlaxoSmithKline acquired TESARO.
- In November 2016, Eagle Pharmaceuticals acquire Arsia Therapeutics.